ArticleGynecology and pelvic medicine2025
Association of
Article in Gynecology and pelvic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fallopian tube carcinoma is one of the most malignant gynecological tumors, with its exact etiology remaining largely unclear. Genetic factors contribute to ~20% of ovarian, fallopian tube, and peritoneal cancers, and gene polymorphisms, including those in non-coding RNAs (ncRNAs) like SNHG17 and CDKN2B-AS1, are linked to gynecologic malignancies. However, research on such polymorphisms in fallopian tube carcinoma is scarce, especially regarding these two genes. Given the correlation between chronic inflammation and malignant tumors (including fallopian tube carcinoma), this study explores the association between SNHG17/CDKN2B-AS1 polymorphisms and susceptibility to salpingitis and high-grade serous fallopian tube carcinoma (HGSC). Methods: A case-control study was conducted, enrolling 194 salpingitis cases, 195 HGSC cases, and 206 normal controls. Specimens (paraffin-embedded fallopian tube tissue wax blocks) were collected from June 2015 to December 2019. Genomic DNA was extracted, and genotyping of SNHG17 rs1578462, CDKN2B-AS1 rs3217992, and rs4977756 was performed using restriction fragment length polymorphism polymerase chain reaction (RFLP-PCR). Hardy-Weinberg equilibrium (HWE) was assessed in the control group. Genetic association analyses included allelic, additive, dominant, and recessive models for each single nucleotide polymorphism (SNP): rs1578462, rs3217992, and rs4977756 were all tested under these four models. Stratification analyses were performed by calculating odds ratios (ORs) with corresponding 95% confidence intervals (CIs). Results: Significant associations were detected between the minor allele genotypes of SNHG17 SNP rs1578462 and HGSC susceptibility, with the CC genotype significantly associated with a decreased risk of HGSC. The genotype of rs3217992 may be associated with higher International Federation of Gynecology and Obstetrics (FIGO) stages, while the genotype of rs4977756 may be associated with lymphatic metastasis. Additionally, the combined genotypes of rs1578462-rs3217992 and rs3217992-rs4977756 may be related to HGSC. Regarding salpingitis, no significant associations were observed between the three SNPs (rs1578462, rs3217992, rs4977756) and salpingitis susceptibility (all P>0.05). Conclusions: To our knowledge, our study is the first to report that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.